A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT02611323 · COMPLETED
Trial details
- NCT number
- NCT02611323
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-09
- Primary completion
- 2022-08-04
- Enrollment
- 133
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.